The roles of mesenchymal stem cells in tumor inflammatory microenvironment

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Sun, Zhao ^a   Wang, Shihua ^b   Zhao, Robert Chunhua ^a,b  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Inflammatory microenvironment; Mesenchymal stem cell; Tumor

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CD31 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CXCR4; CYCLIN D2; ENHANCED GREEN FLUORESCENT PROTEIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON; GRANULOCYTE CHEMOTACTIC PROTEIN 2; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MYC PROTEIN; PLATELET DERIVED GROWTH FACTOR; PROSTAGLANDIN F; STROMAL CELL DERIVED FACTOR 1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADIPOSE TISSUE; CANCER STEM CELL; CELL ACTIVATION; CELL ADHESION; CELL DIFFERENTIATION; CELL HOMING; CELL PROLIFERATION; CHROMOSOME ABERRATION; CYTOKINE PRODUCTION; CYTOTOXICITY; EWING SARCOMA; HUMAN; LUNG NON SMALL CELL CANCER; MESENCHYMAL STEM CELL; METASTASIS; NEUROBLASTOMA; REVIEW; RHABDOMYOSARCOMA; TERATOMA; TUMOR GROWTH; TUMOR INFLAMMATORY MICROENVIRONMENT; TUMOR INVASION; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIUM; WNT SIGNALING PATHWAY; ANIMAL; CELL GROWTH; MESENCHYMAL STROMA CELL; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL GROWTH PROCESSES; HUMANS; MESENCHYMAL STROMAL CELLS; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MICROENVIRONMENT;

EID: 84896779371     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-14     Document Type: Review

References (83)

1. The hallmarks of cancer. Hanahan D, Weinberg RA, Cell 2000 100 1 57 70 10.1016/S0092-8674(00)81683-9 10647931
2. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Calon A, Espinet E, Palomo-Ponce S, Tauriello DV, Iglesias M, Cespedes MV, et al. Cancer Cell 2012 22 5 571 584 10.1016/j.ccr.2012.08.013 23153532
3. Cancers as wounds that do not heal: differences and similarities between renal regeneration/repair and renal cell carcinoma. Riss J, Khanna C, Koo S, Chandramouli GV, Yang HH, Hu Y, et al. Cancer Res 2006 66 14 7216 7224 10.1158/0008-5472.CAN-06-0040 16849569
4. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A, Cancer Res 2012 72 16 3977 3986 10.1158/0008-5472.CAN-12-0938 22719066
5. The tumor microenvironment and its role in promoting tumor growth. Whiteside TL, Oncogene 2008 27 45 5904 5912 10.1038/onc.2008.271 18836471
6. Creating a tumor-resistant microenvironment: cell-mediated delivery of TNFalpha completely prevents breast cancer tumor formation in vivo. Al-Zoubi M, Salem AF, Martinez-Outschoorn UE, Whitaker-Menezes D, Lamb R, Hulit J, et al. Cell Cycle 2013 12 3 480 490 10.4161/cc.23370 23292149
7. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-gamma and GM-CSF. Spear P, Barber A, Rynda-Apple A, Sentman CL, J Immunol 2012 188 12 6389 6398 10.4049/jimmunol. 1103019 22586039
8. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, et al. Clin Cancer Res 2013 19 5 1225 1231 10.1158/1078-0432.CCR-12-1630 23307859
9. Syndecan-1 modulates beta-integrin-dependent and interleukin-6-dependent functions in breast cancer cell adhesion, migration, and resistance to irradiation. Hassan H, Greve B, Pavao MS, Kiesel L, Ibrahim SA, Gotte M, FEBS J 2013 280 10 2216 2227 10.1111/febs.12111 23289672
10. Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Munson JM, Bellamkonda RV, Swartz MA, Cancer Res 2013 73 5 1536 1546 10.1158/0008-5472.CAN-12-2838 23271726
11. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Gorgun GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, et al. Blood 2013 121 15 2975 2987 10.1182/blood-2012-08-448548 23321256
12. MSC and Tumors: Homing, Differentiation, and Secretion Influence Therapeutic Potential. D'Souza N, Burns JS, Grisendi G, Candini O, Veronesi E, Piccinno S, et al. Adv Biochem Eng Biotechnol 2012 Epub ahead of print, doi:10.1007/10-2012-150.
13. Clinical applications of mesenchymal stem cells. Wang S, Qu X, Zhao RC, J Hematol Oncol 2012 5 19 10.1186/1756-8722-5-19 22546280
14. The different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromes. Zhao Z, Wang Z, Li Q, Li W, You Y, Zou P, PLoS One 2012 7 9 45675 10.1371/journal.pone.0045675 23029178
15. Impairment in immuno-modulatory function of Flk1(+)CD31(-)CD34(-) MSCs from MDS-RA patients. Han Q, Sun Z, Liu L, Chen B, Cao Y, Li K, et al. Leuk Res 2007 31 11 1469 1478 10.1016/j.leukres.2006.12.016 17360037
16. Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia. Pontikoglou C, Kastrinaki MC, Klaus M, Kalpadakis C, Katonis P, Alpantaki K, et al. Stem Cells Dev 2013 22 9 1329 1341 10.1089/scd.2012.0255 23249221
17. Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D, et al. Leukemia 2012 26 12 2546 2549 10.1038/leu.2012.126 22652628
18. p53 activation of mesenchymal stromal cells partially abrogates microenvironment-mediated resistance to FLT3 inhibition in AML through HIF-1alpha-mediated down-regulation of CXCL12. Kojima K, McQueen T, Chen Y, Jacamo R, Konopleva M, Shinojima N, et al. Blood 2011 118 16 4431 4439 10.1182/blood-2011-02-334136 21868571
19. Critical features of FAK-expressing AML bone marrow microenvironment through leukemia stem cell hijacking of mesenchymal stromal cells. Despeaux M, Labat E, Gadelorge M, Prade N, Bertrand J, Demur C, et al. Leukemia 2011 25 11 1789 1793 10.1038/leu.2011.145 21647157
20. Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Balakrishnan K, Burger JA, Quiroga MP, Henneberg M, Ayres ML, Wierda WG, et al. Blood 2010 116 7 1083 1091 10.1182/blood-2009- 10-246199 20442367
21. CCR2-dependent recruitment of macrophages by tumor-educated mesenchymal stromal cells promotes tumor development and is mimicked by TNFalpha. Ren G, Zhao X, Wang Y, Zhang X, Chen X, Xu C, et al. Cell Stem Cell 2012 11 6 812 824 10.1016/j.stem.2012.08.013 23168163
22. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Zhu Y, Sun Z, Han Q, Liao L, Wang J, Bian C, et al. Leukemia 2009 23 5 925 933 10.1038/leu.2008.384 19148141
23. Therapeutic potential of mesenchymal stromal cells in a mouse breast cancer metastasis model. Sun B, Roh KH, Park JR, Lee SR, Park SB, Jung JW, et al. Cytotherapy 2009 11 3 289 298 281 p following 298 10.1080/14653240902807026 19308770
24. Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling. Luo J, Ok Lee S, Liang L, Huang CK, Li L, Wen S, et al. Oncogene 2013 Epub ahead of print. doi:10.1038/onc.2013.233.
25. Mesenchymal stem cells provide an advantageous tumor microenvironment for the restoration of cancer stem cells. Nishimura K, Semba S, Aoyagi K, Sasaki H, Yokozaki H, Pathobiology 2012 79 6 290 306 10.1159/000337296 22688186
26. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, et al. PLoS One 2012 7 2 30563 10.1371/journal.pone. 0030563 22363446
27. NF-kappaB activity regulates mesenchymal stem cell accumulation at tumor sites. Uchibori R, Tsukahara T, Mizuguchi H, Saga Y, Urabe M, Mizukami H, et al. Cancer Res 2013 73 1 364 372 10.1158/0008-5472.CAN-12-0088 23066037
28. Mesenchymal stem cells transmigrate between and directly through tumor necrosis factor-alpha-activated endothelial cells via both leukocyte-like and novel mechanisms. Teo GS, Ankrum JA, Martinelli R, Boetto SE, Simms K, Sciuto TE, et al. Stem Cells 2012 30 11 2472 2486 10.1002/stem.1198 22887987
29. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F, et al. Cancer Res 2011 71 2 614 624 10.1158/0008-5472.CAN-10-0538 21224357
30. Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Lin G, Yang R, Banie L, Wang G, Ning H, Li LC, et al. Prostate 2010 70 10 1066 1073 10.1002/pros.21140 20232361
31. Activation of signal transducers and activators of transcription 3 and focal adhesion kinase by stromal cell-derived factor 1 is required for migration of human mesenchymal stem cells in response to tumor cell-conditioned medium. Gao H, Priebe W, Glod J, Banerjee D, Stem Cells 2009 27 4 857 865 10.1002/stem.23 19350687
32. Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Shi M, Li J, Liao L, Chen B, Li B, Chen L, et al. Haematologica 2007 92 7 897 904 10.3324/haematol.10669 17606439
33. Hypoxia-inducible factor-dependent breast cancer-mesenchymal stem cell bidirectional signaling promotes metastasis. Chaturvedi P, Gilkes DM, Wong CC, Luo W, Zhang H, Wei H, et al. J Clin Invest 2013 123 1 189 205 23318994
34. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Rattigan Y, Hsu JM, Mishra PJ, Glod J, Banerjee D, Exp Cell Res 2010 316 20 3417 3424 10.1016/j.yexcr.2010.07.002 20633553
35. Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Senst C, Nazari-Shafti T, Kruger S, Honer Zu Bentrup K, Dupin CL, Chaffin AE, et al. Breast Cancer Res Treat 2013 137 1 69 79 10.1007/s10549-012-2321-0 23143214
36. Human bone marrow-derived MSCs can home to orthotopic breast cancer tumors and promote bone metastasis. Goldstein RH, Reagan MR, Anderson K, Kaplan DL, Rosenblatt M, Cancer Res 2010 70 24 10044 10050 10.1158/0008-5472.CAN-10- 1254 21159629
37. Matrix metalloproteinase 1 is necessary for the migration of human bone marrow-derived mesenchymal stem cells toward human glioma. Ho IA, Chan KY, Ng WH, Guo CM, Hui KM, Cheang P, et al. Stem Cells 2009 27 6 1366 1375 10.1002/stem.50 19489099
38. Glioma cells promote the expression of vascular cell adhesion molecule-1 on bone marrow-derived mesenchymal stem cells: a possible mechanism for their tropism toward gliomas. Hu Y, Cheng P, Xue YX, Liu YH, J Mol Neurosci 2012 48 1 127 135 10.1007/s12031-012-9784-7 22562815
39. Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, et al. Clin Cancer Res 2007 13 17 5020 5027 10.1158/1078-0432.CCR-07-0731 17785552
40. The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells. Coffelt SB, Marini FC, Watson K, Zwezdaryk KJ, Dembinski JL, LaMarca HL, et al. Proc Natl Acad Sci U S A 2009 106 10 3806 3811 10.1073/pnas.0900244106 19234121
41. Tumour-associated fibroblasts and mesenchymal stem cells: more similarities than differences. Paunescu V, Bojin FM, Tatu CA, Gavriliuc OI, Rosca A, Gruia AT, et al. J Cell Mol Med 2011 15 3 635 646 10.1111/j.1582-4934. 2010.01044.x 20184663
42. Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers. Grisendi G, Bussolari R, Veronesi E, Piccinno S, Burns JS, De Santis G, et al. Am J Cancer Res 2011 1 6 787 805 22016827
43. Bone marrow-derived myofibroblasts are the providers of pro-invasive matrix metalloproteinase 13 in primary tumor. Lecomte J, Masset A, Blacher S, Maertens L, Gothot A, Delgaudine M, et al. Neoplasia 2012 14 10 943 951 23097628
44. Tissue-resident stem cells promote breast cancer growth and metastasis. Muehlberg FL, Song YH, Krohn A, Pinilla SP, Droll LH, Leng X, et al. Carcinogenesis 2009 30 4 589 597 10.1093/carcin/bgp036 19181699
45. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Shinagawa K, Kitadai Y, Tanaka M, Sumida T, Kodama M, Higashi Y, et al. Int J Cancer 2010 127 10 2323 2333 10.1002/ijc.25440 20473928
46. Mesenchymal stem cells in non-small cell lung cancer-different from others? Insights from comparative molecular and functional analyses. Gottschling S, Granzow M, Kuner R, Jauch A, Herpel E, Xu EC, et al. Lung Cancer 2013 80 1 19 29 10.1016/j.lungcan.2012.12.015 23294501
47. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Suzuki K, Sun R, Origuchi M, Kanehira M, Takahata T, Itoh J, et al. Mol Med 2011 17 7-8 579 587 21424106
48. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. McLean K, Gong Y, Choi Y, Deng N, Yang K, Bai S, et al. J Clin Invest 2011 121 8 3206 3219 10.1172/JCI45273 21737876
49. Mesenchymal stromal cells from primary osteosarcoma are non-malignant and strikingly similar to their bone marrow counterparts. Brune JC, Tormin A, Johansson MC, Rissler P, Brosjo O, Lofvenberg R, et al. Int J Cancer 2011 129 2 319 330 10.1002/ijc.25697 20878957
50. Colon cancer mesenchymal stem cells modulate the tumorigenicity of colon cancer through interleukin 6. Lin JT, Wang JY, Chen MK, Chen HC, Chang TH, Su BW, et al. Exp Cell Res 2013 319 14 2216 2229 10.1016/j.yexcr.2013.06.003 23751564
51. Mesenchymal stem cell-like cells derived from human gastric cancer tissues. Cao H, Xu W, Qian H, Zhu W, Yan Y, Zhou H, et al. Cancer Lett 2009 274 1 61 71 10.1016/j.canlet.2008.08.036 18849111
52. Mesenchymal stem cells isolated from human uterine cervix cancer tissues. Sun X, Cai H, Qian H, Zhu W, Yan Y, Xu H, et al. Cell Biol Int 2011 35 2 119 123 10.1042/CBI20100132 20874707
53. Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma. Hernanda PY, Pedroza-Gonzalez A, van der Laan LJ, Broker ME, Hoogduijn MJ, Ijzermans JN, et al. Carcinogenesis 2013
54. Isolation and comparison of mesenchymal stem-like cells from human gastric cancer and adjacent non-cancerous tissues. Xu X, Zhang X, Wang S, Qian H, Zhu W, Cao H, et al. J Cancer Res Clin Oncol 2011 137 3 495 504 10.1007/s00432-010-0908-6 20473524
55. Comparison of the characteristics of mesenchymal stem cells obtained from prostate tumors and from bone marrow cultured in conditioned medium. Ding G, Shao J, Ding Q, Fang Z, Wu Z, Xu J, et al. Exp Ther Med 2012 4 4 711 715 23170131
56. Tumour stromal cells derived from paediatric malignancies display MSC-like properties and impair NK cell cytotoxicity. Johann PD, Vaegler M, Gieseke F, Mang P, Armeanu-Ebinger S, Kluba T, et al. BMC Cancer 2010 10 501 10.1186/1471-2407-10-501 20858262
57. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. Ramasamy R, Lam EW, Soeiro I, Tisato V, Bonnet D, Dazzi F, Leukemia 2007 21 2 304 310 10.1038/sj.leu.2404489 17170725
58. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, Cong C, et al. Cancer Biol Ther 2008 7 2 245 251 10.4161/cbt.7.2.5296 18059192
59. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Qiao L, Xu ZL, Zhao TJ, Ye LH, Zhang XD, Cancer Lett 2008 269 1 67 77 10.1016/j.canlet.2008.04.032 18571836
60. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Qiao L, Xu Z, Zhao T, Zhao Z, Shi M, Zhao RC, et al. Cell Res 2008 18 4 500 507 10.1038/cr.2008.40 18364678
61. Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin's lymphoma xenografts. Secchiero P, Zorzet S, Tripodo C, Corallini F, Melloni E, Caruso L, et al. PLoS One 2010 5 6 11140 10.1371/journal.pone.0011140 20585401
62. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Otsu K, Das S, Houser SD, Quadri SK, Bhattacharya S, Bhattacharya J, Blood 2009 113 18 4197 4205 10.1182/blood-2008-09-176198 19036701
63. Human bone marrow-derived mesenchymal stem cells suppress human glioma growth through inhibition of angiogenesis. Ho IA, Toh HC, Ng WH, Teo YL, Guo CM, Hui KM, et al. Stem Cells 2013 31 1 146 155 10.1002/stem.1247 23034897
64. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice. Huang WH, Chang MC, Tsai KS, Hung MC, Chen HL, Hung SC, Oncogene 2013 32 37 4343 4354 10.1038/onc.2012.458 23085755
65. CD133: a stem cell biomarker and beyond. Li Z, Exp Hematol Oncol 2013 2 1 17 10.1186/2162-3619-2-17 23815814
66. Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Xu WT, Bian ZY, Fan QM, Li G, Tang TT, Cancer Lett 2009 281 1 32 41 10.1016/j.canlet.2009.02.022 19342158
67. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Nature 2007 449 7162 557 563 10.1038/nature06188 17914389
68. Mesenchymal stem cells in early entry of breast cancer into bone marrow. Corcoran KE, Trzaska KA, Fernandes H, Bryan M, Taborga M, Srinivas V, et al. PLoS One 2008 3 6 2563 10.1371/journal.pone.0002563 18575622
69. Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Tsukamoto S, Honoki K, Fujii H, Tohma Y, Kido A, Mori T, et al. Int J Oncol 2012 40 1 163 169 21971610
70. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: stimulation of epithelial to mesenchymal transition (EMT). Martin FT, Dwyer RM, Kelly J, Khan S, Murphy JM, Curran C, et al. Breast Cancer Res Treat 2010 124 2 317 326 10.1007/s10549-010-0734-1 20087650
71. Human mesenchymal stem cell and epithelial hepatic carcinoma cell lines in admixture: concurrent stimulation of cancer-associated fibroblasts and epithelial-to-mesenchymal transition markers. Bhattacharya SD, Mi Z, Talbot LJ, Guo H, Kuo PC, Surgery 2012 152 3 449 454 10.1016/j.surg.2012.06.011 22938903
72. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, et al. Blood 2003 102 10 3837 3844 10.1182/blood-2003-04-1193 12881305
73. Adipose derived stem cells (ASCs) isolated from breast cancer tissue express IL-4, IL-10 and TGF-beta1 and upregulate expression of regulatory molecules on T cells: do they protect breast cancer cells from the immune response? Razmkhah M, Jaberipour M, Erfani N, Habibagahi M, Talei AR, Ghaderi A, Cell Immunol 2011 266 2 116 122 10.1016/j.cellimm.2010.09.005 20970781
74. In vitro evidence of the presence of mesenchymal stromal cells in cervical cancer and their role in protecting cancer cells from cytotoxic T cell activity. Montesinos JJ, Mora-Garcia Mde L, Mayani H, Flores-Figueroa E, Garcia-Rocha R, Fajardo-Orduna GR, et al. Stem Cells Dev 2013 22 18 2508 2519 10.1089/scd.2013.0084 23656504
75. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, et al. J Biol Chem 2011 286 28 25007 25015 10.1074/jbc.M110.213108 21592963
76. Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. Waterman RS, Henkle SL, Betancourt AM, PLoS One 2012 7 9 45590 10.1371/journal.pone.0045590 23029122
77. Mesenchymal stem cells regulate epithelial-mesenchymal transition and tumor progression of pancreatic cancer cells. Kabashima-Niibe A, Higuchi H, Takaishi H, Masugi Y, Matsuzaki Y, Mabuchi Y, et al. Cancer Sci 2013 104 2 157 164 10.1111/cas.12059 23121112
78. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Cho JA, Park H, Lim EH, Lee KW, Int J Oncol 2012 40 1 130 138 21904773
79. Immunosuppressive effect of bone marrow-derived mesenchymal stem cells in inflammatory microenvironment favours the growth of B16 melanoma cells. Han Z, Tian Z, Lv G, Zhang L, Jiang G, Sun K, et al. J Cell Mol Med 2011 15 11 2343 2352 10.1111/j.1582-4934.2010.01215.x 21091630
80. Interleukin-1alpha induces immunosuppression by mesenchymal stem cells promoting the growth of prostate cancer cells. Cheng J, Li L, Liu Y, Wang Z, Zhu X, Bai X, Mol Med Rep 2012 6 5 955 960 22895682
81. Mesenchymal stem cells in inflammation microenvironment accelerates hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition. Jing Y, Han Z, Liu Y, Sun K, Zhang S, Jiang G, et al. PLoS One 2012 7 8 43272 10.1371/journal.pone.0043272 22952657
82. TNFalpha-exposed bone marrow-derived mesenchymal stem cells promote locomotion of MDA-MB-231 breast cancer cells through transcriptional activation of CXCR3 ligand chemokines. Shin SY, Nam JS, Lim Y, Lee YH, J Biol Chem 2010 285 40 30731 30740 10.1074/jbc.M110.128124 20650898
83. Exosomes from ovarian cancer cells induce adipose tissue-derived mesenchymal stem cells to acquire the physical and functional characteristics of tumor-supporting myofibroblasts. Cho JA, Park H, Lim EH, Kim KH, Choi JS, Lee JH, et al. Gynecol Oncol 2011 123 2 379 386 10.1016/j.ygyno.2011.08.005 21903249